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Human mesenchymal stem cells pretreatment with IL-17A (MSC-17) potently enhances T cell immunosuppression but not their
immunogenicity, in addition to avidly promoting the induction of suppressive regulatoryT cells.The aimof this studywas to identify
potential mechanisms by which humanMSC-17 mediate their superior immunomodulatory function. Untreated-MSC (UT-MSC),
IFN-𝛾 treated MSC (MSC-𝛾), and MSC-17 were assessed for their gene expression profile by microarray. Significantly regulated
genes were identified for their biological functions (Database for Annotation, Visualisation and Integrated Discovery, DAVID).
Microarray analyses identified 1278 differentially regulated genes betweenMSC-𝛾 and UT-MSC and 67 genes betweenMSC-17 and
UT-MSC. MSC-𝛾 were enriched for genes involved in immune response, antigen processing and presentation, humoral response,
and complement activation, consistent with increased MSC-𝛾 immunogenicity. MSC-17 genes were associated with chemotaxis
response, which may be involved in T cell recruitment for MSC-17 immunosuppression. MMP1, MMP13, and CXCL6 were highly
and specifically expressed in MSC-17, which was further validated by real-time PCR. Thus, MMPs and chemokines may play a
key role in mediating MSC-17 superior immunomodulatory function. MSC-17 represent a potential cellular therapy to suppress
immunological T cell responses mediated by expression of an array of immunoregulatory molecules.
1. Introduction
Humanbonemarrowderivedmesenchymal stemcells (MSC)
pretreated with interleukin-17A (IL-17A) represent a novel
immunomodulatory strategy and an alternative to interferon-
gamma (IFN-𝛾) treatment ofMSC in enhancingMSC immu-
nosuppression of T cells [1]. We have previously demon-
strated that human MSC-17 potently suppresses human T
cell proliferation and activation. In cocultures of MSC with
purified human CD4+CD25− T cells, MSC-17 induced high
numbers of functionally suppressive iTregs [1]. Whilst MSC-
17 appeared to be superiormodulators of T cells, mechanisms
exclusive to MSC-17 mediated immunomodulation warrant
further investigation.
IL-17A is a member of the family of IL-17 cytokines
secreted predominantly by the T helper 17 (Th17) subset of
CD4+ T cells. IL-17A is a potent proinflammatory mediator
and is involved in the pathogenesis of autoimmune dis-
eases, allergic responses, and other immune cell mediated
diseases including allograft rejection, sepsis, and graft versus
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host disease (GvHD) [2, 3]. Apart from the pathogenic
roles of IL-17A, this cytokine is important for host defense
response against fungal and bacterial infections [3, 4]. The
IL-17A homodimer signals through the IL-17RA and IL-
17RC dimeric receptor complex, where binding of IL-17A
homodimer to the IL-17RA/RC complex recruits the key
cytosolic adaptor molecule Act1 (NF-kappa B-activating
protein), that is known to be the master mediator of
downstream IL-17 signaling [3, 5]. Act1 binds to the IL-
17RA/RC complex via its SEFIR (SEF/IL-17R) domains and
this complex then recruits TRAF6 (TNF receptor-associated
factor 6), leading to the activation of several downstream
signaling pathways including the MAPKs-AP-1 (mitogen-
activated protein kinases, MAPKs; activator protein-1, AP-
1), C/EBPs (CCAAT/enhancer-binding proteins) and NF𝜅B
(nuclear factor kappa B). Activation of these signaling cas-
cades induces the gene expression of antimicrobial pep-
tides, chemokines,MMPs, and proinflammatory cytokines as
shown in other cell types such as endothelial cells, epithelial
cells, and fibroblasts [3, 4]. IL-17A has emerged to be a growth
factor for MSC by activating the Akt-Erk-MEK-p38 trans-
duction molecules involved in MAPK signaling cascades [6–
8]. Published work from our laboratory, demonstrated for the
first time that IL-17A also enhances the immunomodulatory
capacity of human MSC [1].
IFN-𝛾 is produced predominantly by CD8+ T cells and
NK cells and at lower levels by CD4+ T cells [9]. IFN-𝛾 binds
to a heterodimeric cell surface receptor complex consisting
of the interferon-gamma receptor 1 (IFNGR1) and IFGR2,
activating the classical JAK-STAT (signal transducer and
activator of transcription) signaling pathways [10]. Activation
of this pathway regulates several downstream cascades and
induces expression ofmany genes, thereby contributing to the
diverse biological effects of IFN-𝛾 in different cell types [10–
12]. IFN-𝛾 activates macrophages to induce antitumor [13]
and antimicrobial activities [14]. It is also well established that
IFN-𝛾 induces antigen processing and presentation pathways
in different cell types for MHC antigen presentation to T
cells [9, 15–17]. In B cells, IFN-𝛾 regulates immunoglobulin
production and class switching [16, 18]. IFN-𝛾 also attracts
leukocytes and favours the growth, differentiation, and mat-
uration of many cells types [11, 16]. IFN-𝛾 is classically known
as a cytokine that favours Th1 cell development [16, 19].
In an allotransplantation setting, IFN-𝛾 promotes antigen-
specific Th1 differentiation that drives cell mediated allograft
rejection [20]. Together, these findings suggest the potent
proinflammatory role of IFN-𝛾.
The role of IFN-𝛾 in MSC immunomodulation, repara-
tive properties, and homing potential has been extensively
reviewed as previously published [21]. IFN-𝛾 treated MSC
(MSC-𝛾) have enhanced immunomodulatory properties but
are potentially immunogenic when administered in allo-
geneic or third-party hosts [1]. In this study, microarray
and bioinformatics approaches were used to further identify
novel candidate molecules expressed by MSC-𝛾 and MSC-
17 that enhance the immunomodulatory properties of MSC.
Genes and biological processes thatmay contribute toMSC-𝛾
immunogenicity in allogeneic or third-party hosts were also
explored.
2. Materials and Methods
2.1.MSCCulture andCharacterisation. Humanbonemarrow
aspirates were obtained from the posterior iliac crest of
normal adults volunteers (subjects with informed consent;
age 20–35 yr) according to guidelines approved by theHuman
Ethics Committee of the Royal Adelaide Hospital, Australia
(Protocol 940911a). Bone marrow derived MSC cultures
were established and maintained as previously described
[22, 23]. Cryopreserved MSC were cultured to log-phase and
used at passage 6 in experiments. The immunophenotype of
culture expanded MSC and their ability to differentiate into
adipocytes, osteocytes, or chondrocytes have been confirmed
and published [1].
2.2. Cytokine Treatment of MSC. MSC were seeded in tissue
culture flasks at a density of 4000 cells/cm2 and were allowed
to adhere overnight. Fresh MSC media containing either no
cytokines or recombinant human cytokines, 500U/ml IFN-
𝛾 (eBioscience) or 50 ng/ml IL-17A (Peprotech), were added
to the MSC cultures to derive UT-MSC, MSC-𝛾, or MSC-
17, respectively. At day 5, cytokines were washed out with
Hank’s Balanced Salt Solution (HBSS, Sigma) and modified
MSC were used for microarray gene expression profiling and
analysis.
2.3. Human MSC RNA Isolation. MSC were harvested using
0.25% trypsin/EDTA (Sigma) for 4min, 37∘C, and rinsed
with 5% FBS/HBSS and RNA was extracted according to
the protocol established by the Adelaide Microarray Centre
(http://www.microarray.adelaide.edu.au/protocols/). Briefly,
total RNA was extracted by dissolving the cell pellet in
500𝜇L TRIzol reagent (Invitrogen) and 100 𝜇L chloroform
was added to the mixture. The mixture was kept on ice
for 15min followed by centrifugation at 6500×g for 30min,
4∘C. The upper aqueous phase was retained and mixed with
an equal volume of 70% ethanol in diethylpyrocarbonate
H2O. Total RNA was further purified using the RNeasy
mini kit (Qiagen) with the following modification: DNA was
digested using the DNase I from the RNase-free DNase set
(Qiagen). The quantity of total RNA was measured using
NanoDrop 1000 (Thermo Scientific). Samples were adjusted
to a concentration of 100 ng/𝜇L for microarray and were sent
to theAdelaideMicroarrayCentre,University ofAdelaide, for
microarray gene expression profiling. The RNA sample was
determined using the Agilent RNA Bioanalyzer. Only RNA
samples with RNA integrity number (RIN) of ≥8 were used
for microarray analysis.
2.4. Microarray Analysis. RNA extracted from human MSC
samples were analysed using the Affymetrix Human Gene
2.0 ST Array (Affymetrix Inc., High Wycombe, UK) for gene
expression profiling. Microarray gene expression profiling
was performed on UT-MSC, MSC-𝛾 and MSC-17 from 3
humanMSCdonor biological replicates (passage 6).Microar-
ray experiments were conducted by the Adelaide Microarray
Centre, University of Adelaide.
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2.5.MicroarrayQuality Control andGene ExpressionAnalysis.
Probe cell intensity (CEL) files were obtained from the Ade-
laide Microarray Centre. The Expression Console Software
(Affymetrix)was used for data quality control, normalization,
and differential gene level analysis. CEL files of each array
showed no major issues or damage with the images. No
outlier samples were identified based on the configurable
QA/QC metrics. The RMA (robust multiarray analysis)
algorithm was used to perform background subtraction,
normalization, and summarization of probe sets. CHP files
were generated from the Expression Console Software for
further Principal Component Analysis (PCA) and gene level
summarization using the Transcriptome Analysis Console
(TAC) software (Affymetrix). After normalization, UT-MSC,
MSC-𝛾, andMSC-17 from 3 donor samples of each treatment
group were averaged and an unpaired one-way ANOVA
was performed with significantly regulated genes identified
by 𝑝 < 0.05 and fold changes < −2 and >2. Gene lists
for comparison of MSC-17 versus UT-MSC, MSC-𝛾 versus
UT-MSC, and MSC-17 versus MSC-𝛾 were generated for
subsequent bioinformatics analysis.
2.6. Functional Enrichment Analysis by DAVID. Gene lists
for comparison of MSC-17 versus UT-MSC, MSC-𝛾 versus
UT-MSC, and MSC-17 versus MSC-𝛾 were analysed for
their biological functions using the Database for Anno-
tation, Visualisation and Integrated Discovery (DAVID;
https://david.ncifcrf.gov/). The gene list was uploaded using
the official gene symbol onto DAVID for functional anno-
tation clustering analysis with medium classification strin-
gency, enrichment scores > 1.5, and 𝑝 < 0.05 [24]. Func-
tional annotation clustering analysis based on DAVID’s
default settings was performed. The gene sets were also
subcategorised based on functional annotation of interest
such as biological process (GOTERM BP FAT), molecu-
lar function (GOTERM MF FAT), and cellular component
(GOTERM CC FAT).
2.7. Real-Time PCR Gene Validation. Genes of interest
identified by microarray were validated by real-time
PCR (RT-PCR) as previously described [1]. Gene specific
human Taqman primers MMP1 (Hs00899659 m1),
MMP13 (Hs00233992 ml), CCL2 (Hs00234140 m1),
CCL8 (Hs04187715 m1), CXCL6 (Hs00605742 m1), C3
(Hs00163811 ml), CH25H (Hs02379634 s1), and LBP
(Hs01084621 ml) (Applied Biosystems) were used for gene
expression analysis. Samples were run in triplicate and
data were presented and normalized to the housekeeping
gene hypoxanthine phosphoribosyltransferase-1 (HPRT1)
(Hs99999909 ml). Mean normalized expression was
calculated using the Qgene Module software as previously
described [25].
3. Results
3.1. Transcriptome Profiling of UT-MSC, MSC-𝛾, and MSC-
17. Thetranscriptomedifferences betweenUT-MSC,MSC-𝛾,
and MSC-17 from 3 different humanMSC donors were com-












PCA: RMA-GENE-FULL, Group 2 (PCA Mapping 68.1%)
Figure 1: Principal Component Analysis (PCA) of UT-MSC, MSC-
𝛾, andMSC-17.This 3-dimensional PCA graph identifies a new set of
variables (PCA1, PCA2, and PCA3) that account for majority of the
variability among the samples. PCA1 captures as much variability
in the data as possible, PCA2 captures as much variability of the
remaining variability not accounted by PCA1, and PCA3 captures
as much of the remaining variability not accounted by PCA2. The
symbols indicate IL-17A treated MSC, 17 ; IFN-𝛾 treated MSC (Y );
and untreated-MSC (wt ).The 3 differentMSC donors are indicated
by C, M, and F.
performed to visualise variances between the 3 donors and
treatment groups. PCA analysis revealed that the 3 donor
replicates ofMSC-𝛾 “clustered” together.The gene expression
pattern in the MSC-𝛾 groups were clearly distinct from UT-
MSC and MSC-17 (Figure 1). Microarray analysis revealed
that 1278 genes (902 upregulated; 376 downregulated) were
differentially regulated between MSC-𝛾 and UT-MSC. The
top 30 upregulated and downregulated genes in the MSC-𝛾
were shown in Table 1.
There were however donor variances that exist between
MSC-17 and UT-MSC. Among the 3 MSC donor samples
evaluated, 2 MSC donors (i.e., donor C and F) “clustered”
together andwere distinct fromUT-MSC (Figure 1). It should
also be noted that in donor C and F MSC-17 “clusters,”
there was less variability in the gene expression profile in
MSC-17 versus UT-MSC compared to the MSC-𝛾 versus
UT-MSC groups. Donor M on the contrary had a different
gene expression pattern in both UT-MSC and MSC-17. This
clustering analysis in general supports a lesser degree of
change in the gene expression profile of MSC with IL-17A
than IFN-𝛾. Based on these 3 MSC donors, microarray
analysis identified that only 67 genes (39 upregulated; 28
downregulated) were differentially regulated between MSC-
17 and UT-MSC (Table 2).
The gene expression profile of MSC-17 versus MSC-𝛾was
also evaluated. The clustering of the 3 MSC donors in the
MSC-17 and MSC-𝛾 comparison groups was more distinct
(Figure 1)when compared toMSC-17 andUT-MSC.Microar-
ray analysis revealed that 1806 genes (391 upregulated; 1415
downregulated) were differentially regulated between MSC-
17 and MSC-𝛾. The top 30 upregulated and downregulated
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Table 1: Top 30 differentially expressed genes: MSC-𝛾 versus UT-MSC.
Gene symbol Gene name mRNA Accession Fold change 𝑝 value
Upregulated genes
HLA-DRA Major histocompatibility complex, class II, DR alpha NM 019111 387.78 0.00049
GBP4 Guanylate binding protein 4 NM 052941 199.41 0.00002
IDO1 Indoleamine 2,3-dioxygenase 1 NM 002164 96.72 0.00003
HLA-DRB Major histocompatibility complex, class II, DR beta ENST00000307137 89.67 0.00435
GBP5 Guanylate binding protein 5 NM 052942 88.07 0.00003
CXCL9 Chemokine (C-X-C motif) ligand 9 NM 002416 83.60 0.00002
GBP2 Guanylate binding protein 2, interferon-inducible ENST00000464839 77.00 0.00004
SECTM1 Secreted and transmembrane 1; NULL NM 003004 57.59 0.00002
HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 ENST00000426847 51.65 0.00868
CIITA Class II, major histocompatibility complex,transactivator NM 00024 38.84 0.00003
GBP1 Guanylate binding protein 1, interferon-inducible NM 002053 29.09 0.00001
RP11-44K6.2 NULL ENST00000520185 26.39 0.00060
GCH1 GTP cyclohydrolase 1 NM 000161 24.93 0.00022
USP30-AS1 USP30 antisense RNA 1 ENST00000478808 24.75 0.00009
GBP2 Guanylate binding protein 2, interferon-inducible;NULL NM 004120 23.60 0.00001
HLA-DOA Major histocompatibility complex, class II, DO alpha;NULL NM 002119 22.90 0.00003
IFIT3 Interferon-induced protein with tetratricopeptiderepeats 3 NM 001031683 21.49 0.00013
FAM129A Family with sequence similarity 129, member A NM 052966 20.89 0.00003
CTSS Cathepsin S NM 004079 20.10 0.00002
SLC7A11 Solute carrier family 7 (anionic amino acid transporterlight chain, xc- system), member 11 NM 014331 19.70 0.00009
IRF1 Interferon regulatory factor 1 NM 002198 19.55 0.00002
CD74 CD74 molecule, major histocompatibility complex,class II invariant chain; NULL NM 001025159 18.49 0.00060
ICAM1 Intercellular adhesion molecule 1 NM 000201 18.43 0.00003
HCP5 HLA complex P5 (nonprotein coding); NULL ENST00000457127 18.15 0.00032
LGALS17A Charcot-Leyden crystal protein pseudogene ENST00000412609 18.12 0.00038
PARP14 Poly (ADP-ribose) polymerase family, member 14 NM 017554; 17.05 0.00014
RARRES3 Retinoic acid receptor responder (tazarotene induced) 3 NM 004585 17.00 0.00007
WARS Tryptophanyl-tRNA synthetase; NULL NM 004184 16.49 0.00002
IFIT2 Interferon-induced protein with tetratricopeptiderepeats 2 NM 001547 16.43 0.00051
TMEM140 transmembrane protein 140 NM 018295 16.08 0.00012
Downregulated genes
LRRC15 Leucine rich repeat containing 15 NM 001135057 −19.91 0.0007
KIAA1199 KIAA1199; NULL NM 018689 −13.26 0.0025
RNU5A-8P RNA, U5A small nuclear 8, pseudogene ENST00000364102 −12.36 0.0061
COL10A1 Collagen, type X, alpha 1 NM 000493; −12.25 0.0031
COL3A1 Collagen, type III, alpha 1; microRNA 3606 NM 000090 −11.88 0.0000
HIST1H2A
Histone cluster 1, H2ai; histone cluster 1, H2ah; histone
cluster 1, H2ag; histone cluster 1, H2am; histone cluster
1, H2al; histone cluster 1, H2ak; histone cluster 1, H3f
NM 003509 −11.67 0.0012
SCD Stearoyl-CoA desaturase (delta-9-desaturase) NM 005063 −9.75 0.0000
U2 U2 spliceosomal RNA ENST00000410792 −9.41 0.0476
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Table 1: Continued.
Gene symbol Gene name mRNA Accession Fold change 𝑝 value
HIST1H3
Histone cluster 1, H3b; histone cluster 1, H3f; histone
cluster 1, H3h; histone cluster 1, H3j; histone cluster 1,
H3g; histone cluster 1, H3i; histone cluster 1, H3e;
histone cluster 1, H3c; histone cluster 1, H3d; histone
cluster 1, H3a
NM 003537 −9.06 0.0053
HIST1H1B Histone cluster 1, H1b NM 00532 −8.53 0.0002
— — ENST00000408768 −8.25 0.0001
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulumprotein retention receptor 3 NM 016657 −8.22 0.0007
— — BC091525 −7.87 0.0007
SNORD114-11 Small nucleolar RNA, C/D box 114-11 NR 003204 −7.33 0.0021
WISP1 WNT1 inducible signaling pathway protein 1 NM 003882 −7.18 0.0000
U3 Small nucleolar RNA U3 ENST00000390893 −7.14 0.0128
HIST1H2BM Histone cluster 1, H2bm NM 003521 −6.92 0.0024
COL1A1 Collagen, type I, alpha 1; NULL NM 000088 −6.84 0.0000
HIST1H3
histone cluster 1, H3g; histone cluster 1, H3f; histone
cluster 1, H3b; histone cluster 1, H3h; histone cluster 1,
H3j; histone cluster 1, H3i; histone cluster 1, H3e;
histone cluster 1, H3c; histone cluster 1, H3d; histone
cluster 1, H3a
NM 003534 −6.68 0.0032
HIST1H3
Histone cluster 1, H3f; histone cluster 1, H3b; histone
cluster 1, H3h; histone cluster 1, H3j; histone cluster 1,
H3g; histone cluster 1, H3i; histone cluster 1, H3e;
histone cluster 1, H3c; histone cluster 1, H3d; histone
cluster 1, H3a
NM 021018 −6.41 0.0058
AL732479.1 — ENST00000459197 −6.38 0.0015
ADAM12 ADAMmetallopeptidase domain 12; NULL NM 003474; −6.13 0.0001
ENPP1 Ectonucleotide pyrophosphatase/phosphodiesterase 1 NM 006208 −6.06 0.0002
NDNF Neuron-derived neurotrophic factor NM 024574 −6.00 0.0100
DHCR7 7-Dehydrocholesterol reductase; NULL NM 001360 −5.88 0.0005
DHCR24 24-Dehydrocholesterol reductase NM 014762 −5.84 0.0001
RGS4 Regulator of G-protein signaling 4; NULL NM 001102445 −5.78 0.0116
CRABP2 Cellular retinoic acid binding protein 2 NM 001878 −5.76 0.0015
KIF20A Kinesin family member 20A; NULL NM 005733 −5.60 0.0072
U1 U1 spliceosomal RNA — −5.38 0.0069
genes in the MSC-17 versus MSC-𝛾 comparison group were
shown in Table 3. Volcano plots (Figure 2) and supervised
hierarchical clustering of the differentially expressed genes
(Figure 3) provided a global visualisation of genes regulated
by IL-17 or IFN-𝛾 treatment of MSC compared to UT-MSC.
3.2. MSC-𝛾 Enriched for Genes Associated with Increased
Immunogenicity. Upregulated and downregulated gene lists
were submitted to DAVID for functional annotation clus-
tering analysis to identify gene sets that were enriched in
MSC-𝛾. There were 90 and 62 official gene symbols from
the upregulated (see Table S1 in Supplementary Material
available online at https://doi.org/10.1155/2017/1025820) and
downregulated (Table S2) gene entry lists, respectively, that
were unmapped by DAVID. These were mainly noncoding
genes including microRNA (miRNA), long noncoding RNA
(lncRNA), and small nucleolar RNA (snoRNA). Gene ontol-
ogy analysis by DAVID functional annotation clustering was
performed on the upregulated and downregulated MSC-𝛾
versus UT-MSC gene lists to identify enriched gene sets
for biological processes (Tables S3, S4), molecular functions
(Tables S5, S6), and cellular components (Tables S7, S8).
Gene ontology analysis for biological processes of upreg-
ulated MSC-𝛾 genes (Table S3) uncovered highest enrich-
ment of genes associated with antigen processing and pre-
sentation via MHC class I (annotation cluster 1, enrichment
score 8.03). These genes were mainly HLA type genes
and have roles in antigen presentation. Enriched genes
in annotation cluster 1 also include aminopeptidases that
hydrolyse antigenic peptides for MHC class I peptide bind-
ing and antigen presentation (e.g., endoplasmic reticulum
aminopeptidase ERAP1 and ERAP2), peptide transporter
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Table 2: Differentially expressed genes (mapped by DAVID): MSC-17 versus UT-MSC.
Gene symbol Gene name mRNA Accession Fold change 𝑝 value
Upregulated genes
MMP13 Matrix metallopeptidase 13 (collagenase 3) NM 002427 15.60 0.0021
C3 Complement component 3; NULL NM 000064 11.56 0.0039
LBP Lipopolysaccharide binding protein NM 004139 5.35 0.0031
VMO1 Vitelline membrane outer layer 1 homolog (chicken) NM 182566 4.07 0.0022
CH25H Cholesterol 25-hydroxylase NM 003956 3.99 0.0023
IL6 Interleukin 6 (interferon, beta 2); NULL NM 000600 3.44 0.0083
ZC3H12A Zinc finger CCCH-type containing 12A NM 025079 3.09 0.0010
CCL2 Chemokine (C-C motif) ligand 2 NM 002982 3.08 0.0405
ZNF253 Zinc finger protein 253 NM 021047 2.82 0.0010
SAA1 Serum amyloid A1 NM 000331 2.72 0.0102
CXCL6 Chemokine (C-X-C motif) ligand 6 NM 002993 2.44 0.0014
MMP1 Matrix metallopeptidase 1 (interstitial collagenase) NM 002421 2.40 0.0356
NFKBIZ Nuclear factor of kappa light polypeptide gene enhancer inB-cells inhibitor, zeta; NULL NM 031419 2.36 0.0232
MIRLET7A2 MicroRNA let-7a-2 NR 029477 2.30 0.0031
RBMY2EP RNA binding motif protein, Y-linked, family 2, member Epseudogene ENST00000444169 2.27 0.0278
CCL8 Chemokine (C-C motif) ligand 8 NM 005623 2.20 0.0012
STC1 Stanniocalcin 1 NM 003155 2.20 0.0023
SFRP4 Secreted frizzled-related protein 4 NM 003014 2.19 0.0136
SLC22A3 Solute carrier family 22 (extraneuronal monoaminetransporter), member 3 NM 021977 2.15 0.0452
TTTY11 Testis-specific transcript, Y-linked 11 (nonprotein coding) NR 001548 2.15 0.0252
STEAP2 STEAP family member 2, metalloreductase; NULL NM 001244944 2.12 0.0225
SCARNA18 Small Cajal body-specific RNA 18 NR 003139 2.06 0.0254
LOC100287834 Uncharacterised LOC100287834 NR 028349 2.06 0.0328
Downregulated genes
RPS24 Ribosomal protein S24; NULL NM 001142285 −2.01 0.0209
LOC100133299 GALI1870 AY358688 −2.03 0.0095
POU5F1 POU class 5 homeobox 1 ENST00000259915 −2.04 0.0129
TMEM171 Transmembrane protein 171 NM 173490 −2.05 0.0133
IGLJ2 Immunoglobulin lambda joining 2 ENST00000390322 −2.07 0.0252
ITGA6 Integrin, alpha 6; NULL ENST00000264107 −2.11 0.0109
RNU7-25P RNA, U7 small nuclear 25 pseudogene; RNA, U7 smallnuclear 11 pseudogene ENST00000516544 −2.16 0.0047
GTF2IRD2B GTF2I repeat domain containing 2B NM 001003795 −2.20 0.0040
SERTAD4 SERTA domain containing 4 ENST00000367012 −2.29 0.0470
TPTE Transmembrane phosphatase with tensin homology ENST00000415664 −2.85 0.0128
genes (e.g., transported associated with antigen processing,
TAP2), and other genes involved in the antigen process-
ing and presentation pathway (e.g., TAP binding protein,
TAPBPL; 𝛽2 microglobulin, B2M; CD74). Gene sets involved
with antigen processing and presentation via MHC class
II were also upregulated in the MSC-𝛾 groups (annotation
cluster 4, enrichment score 4.45). In annotation cluster 2
(enrichment score 6.06) there were also enriched gene sets
involved in immune response activation (innate, adaptive,
and lymphocytes mediated immunity), humoral response
(immunoglobulin mediated immune response, B cell medi-
ated immunity, and humoral immune response mediated
by circulating immunoglobulin), and complement pathways
(classical and alternative) activation.
Apart from genes that are involved in increased MSC-
𝛾 immunogenicity, there were genes with regulatory roles
upregulated in MSC-𝛾 (Table S3). For example, these gene
sets were involved in the regulation of programmed cell
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Table 3: Top 30 differentially expressed genes: MSC-17 versus MSC-𝛾.
Gene symbol Gene name mRNA Accession Fold change 𝑝 value
Upregulated genes
MMP13 Matrix metallopeptidase 13 (collagenase 3) NM 002427 24.27 0.0009
HIST1H2AI Histone cluster 1, H2ai NM 003509 17.44 0.0005
U3 Small nucleolar RNA U3 ENST00000390893 13.96 0.0118
ZNF25 Zinc finger protein 25 ENSG00000175395 13.66 0.0008
LRRC15 Leucine rich repeat containing 15 NM 001135057 13.57 0.0005
HIST1H3G Histone cluster 1, H3g NM 003534 12.68 0.0008
SNORD114-11 Small nucleolar RNA, C/D box 114-11 NR 003204 12.33 0.0386
HIST1H3B Histone cluster 1, H3b NM 003537 11.20 0.0064
U1 U1 spliceosomal RNA NONHSAT054977 10.54 0.0017
HIST1H1B Histone cluster 1, H1b NM 005322 10.28 0.0003
SCD Stearoyl-CoA desaturase (delta-9-desaturase) NM 005063 10.15 0.0008
KRT16P4 Keratin 16 pseudogene 4 ENST00000453883 9.11 0.0122
ADAM12 ADAMmetallopeptidase domain 12 NM 001288973 8.96 0.0031
HIST1H2BM Histone cluster 1, H2bm NM 003521 8.87 0.0125
HIST1H3F Histone cluster 1, H3f NM 021018 8.77 0.0081
ADAM12 ADAMmetallopeptidase domain 12 NM 001288973 8.70 0.0121
KIAA1199 KIAA1199; NULL NM 018689 8.48 0.0045
COL10A1 Collagen, type X, alpha 1 NM 000493 6.87 0.0136
DHCR7 7-Dehydrocholesterol reductase; NULL NM 001360 6.51 0.0022
P4HA3 Prolyl 4-hydroxylase, alpha polypeptide III NM 182904 6.49 0.0043
LBP Lipopolysaccharide binding protein NM 004139 6.11 0.0021
HAS1 Hyaluronan synthase 1 NM 001523 6.10 0.0038
COL1A1 Collagen, type I, alpha 1; NULL NM 000088 5.94 0.000002
NDNF Neuron-derived neurotrophic factor NM 024574 5.75 0.0147
ELN Elastin; NULL NM 000501 5.65 0.0014
WISP1 WNT1 inducible signaling pathway protein 1 NM 003882 5.61 0.0052
ADAM12 ADAMmetallopeptidase domain 12; NULL NM 003474 5.56 0.0008
KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulumprotein retention receptor 3 NM 016657 5.36 0.0085
HIST1H3I Histone cluster 1, H3i NM 003533 5.02 0.0014
CNN1 Calponin 1, basic, smooth muscle NM 001299 4.69 0.00001
Downregulated genes
HLA-DRA Major histocompatibility complex, class II, DR alpha NM 019111 −553.64 0.0005
GBP4 Guanylate binding protein 4 NM 052941 −244.27 0.0001
HLA-DRA Major histocompatibility complex, class II, DR alpha;NULL ENST00000442960 −188.10 0.00005
CXCL9 Chemokine (C-X-C motif) ligand 9 NM 002416 −96.44 0.00001
IDO1 Indoleamine 2,3-dioxygenase 1 NM 002164 −76.98 0.00004
HLA-DRB3 Major histocompatibility complex, class II, DR beta 3 ENST00000307137 −70.87 0.0024
GBP5 Guanylate binding protein 5 NM 052942 −65.02 0.000004
SECTM1 Secreted and transmembrane 1; NULL NM 003004 −50.74 0.0001
GBP2 Guanylate binding protein 2, interferon-inducible ENST00000464839 −41.55 0.00001
HLA-DPA1 Major histocompatibility complex, class II, DP alpha1 NM 001242524 −40.79 0.0011
IFIT3 Interferon-induced protein with tetratricopeptiderepeats 3 NM 001031683 −39.52 0.0011
CIITA Class II, major histocompatibility complex,transactivator NM 000246 −37.92 0.000003
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Table 3: Continued.
Gene symbol Gene name mRNA Accession Fold change 𝑝 value
GBP1 Guanylate binding protein 1, interferon-inducible NM 002053 −35.79 0.0002
PSAT1 Phosphoserine aminotransferase 1 NM 021154 −31.20 0.0001
HLA-DPB1 NULL OTTHUMT00000310634 −28.81 0.00002
GBP1P1 Guanylate binding protein 1, interferon-induciblepseudogene 1 ENST00000513638 −27.87 0.00001
GCH1 GTP cyclohydrolase 1 NM 000161 −26.74 0.0002
PARP14 Poly (ADP-ribose) polymerase family, member 14 NM 017554 −26.49 0.0008
IRF1 Interferon regulatory factor 1 NM 002198 −24.92 0.000003
HLA-DOA Major histocompatibility complex, class II, DO alpha NM 002119 −24.00 0.00001
RARRES3 Retinoic acid receptor responder (tazaroteneinduced) 3 NM 004585 −23.10 0.0001
LGALS17A Charcot-Leyden crystal protein pseudogene ENST00000412609 −22.45 0.0003
HLA-DOA Major histocompatibility complex, class II, DO alpha NM 002119 −21.85 0.00001
SLC7A11 Solute carrier family 7 (anionic amino acidtransporter light chain, xc- system), member 11 NM 014331 −21.62 0.00004
USP30-AS1 USP30 antisense RNA 1 ENST00000478808 −20.00 0.0001
HCP5 HLA complex P5 (non-protein coding); NULL ENST00000457127 −19.90 0.0001
ICAM1 Intercellular adhesion molecule 1 NM 000201 −19.63 0.0001
WARS Tryptophanyl-tRNA synthetase; NULL NM 004184 −19.41 0.0001
APOL1 Apolipoprotein L, 1; NULL NM 003661 −19.36 0.00002
ERVK-7 Endogenous retrovirus group K, member 7; noveltranscript ENST00000522373 −18.93 0.0267
HLA-DPB2 Major histocompatibility complex, class II, DP beta 2(pseudogene) NR 001435 −18.91 0.00009
death, apoptosis, translation regulation, protein modifica-
tion, transcription regulation and DNA binding activity,
cell-cell communication, and signal transduction as well
as the regulation of cytokine production. Moreover, genes
upregulated in the MSC-𝛾 group were enriched for the TGF-
𝛽 receptor signaling pathway (annotation cluster 19, enrich-
ment score 1.74, e.g., FMOD, CCL2, MAPK3K1, SMAD6,
GDF15, and TGFB2). Other genes of interest upregulated in
MSC-𝛾 include IL-6, toll-like receptor-3 (TLR3), TLR4, and
indoleamine 2,3-dioxygenase (IDO), with the gene ontology
term for positive regulation of defense response. There was
also upregulation of the PD-L1 transcript inMSC-𝛾 compared
to UT-MSC (3.46-fold, 𝑝 < 0.0104; data not shown),
consistent with the observed increase in cell surface protein
expression of PD-L1 following IFN-𝛾 pretreatment of MSC,
as we have previously published [1]. Regulatory genes with
nucleotide binding activity and transcription (corepressor,
repressor, and cofactor) activity were also enriched and
upregulated inMSC-𝛾 as identified by DAVID gene ontology
analysis for molecular function (Table S5).
MSC-𝛾 have enhanced migratory potential to sites of
inflammation [21]. Based on DAVID analysis for biologi-
cal processes, we have identified gene sets in annotation
cluster 10 (enrichment score 2.78) that were enriched for
the gene ontology terms regulation of cell motion, cell
migration, and locomotion (Table S3). These upregulated
MSC-𝛾 genes include chemokines (CXCL10, CXCL16), intra-
cellular adhesion molecule-1 (ICAM1), IL-6, and VEGFA.
The upregulation of chemotactic factors that may increase
MSC-𝛾 homing potential was also identified when gene
ontology analysis for molecular function was performed
on DAVID. In annotation cluster 3 (enrichment score
3.10; Table S5), genes were enriched for chemokine recep-
tor binding and chemokine activity. These chemokines
include CCL13, CCL2, CXCL16, CXCL9, CCL8, CXCL11, and
CXCL10.
Based on the downregulated MSC-𝛾 versus UT-MSC
gene list, we identified that there were genes highly enriched
for the gene ontology terms for biological processes involving
extracellular matrix or structure organisation (annotation
cluster 1, enrichment score 11.10; Table S4), consistent with
our previous observation of changes in MSC-𝛾 morphol-
ogy from fibroblastic-like appearance to a hypertrophic
flattened irregular shape [1]. These were mainly collagen
type genes (collagenases I, III, IV, V, XI, XII, and XIV).
Interestingly, the downregulated gene sets also have enriched
terms for biological processes involved in the cell division
cycle (annotation cluster 2, enrichment score 8.80; Table
S4) These downregulated genes were essential for M phase,
nuclear division, mitosis, and cell division. Genes essential
for regulation of cell-cycle division were also downregulated
in MSC-𝛾 (annotation cluster 7, enrichment score 2.03), in









































































Figure 2: Volcano plots to identify changes in gene expression between (a) MSC-17 versus UT-MSC, (b) MSC-𝛾 versus UT-MSC, and (c)
MSC-17 versus MSC-𝛾. Axes of these plots represent significance (−10 log10 𝑝 value of the ANOVA 𝑝 values; 𝑦-axes) versus fold changes
(linear fold change from condition pairing; 𝑥-axes). Red colour indicates upregulated genes and the green represents downregulated genes.
The grey region indicates genes that were not differentially expressed and not statistically significant.
coherence with the observation of decreased MSC-𝛾 growth
kinetics compared to UT-MSC [1].
Gene ontology analysis for cellular components (Tables
S7, S8) of the differentially regulated genes in the MSC-
𝛾 versus UT-MSC groups uncovered that these genes were
located in the extracellular space (or) region (annotation clus-
ter 1, enrichment score 2.69, Table S7; enrichment score 12.76,
Table S8). Many downregulated genes were located in colla-
gen, the main structural protein in the extracellular region.
3.3. MSC-17 Enriched for Genes Associated with Chemotaxis.
Differentially regulated genes were submitted to DAVID for
functional annotation clustering to identify gene sets that
were enriched inMSC-17.Genes thatweremapped byDAVID
were shown in Table 2. There were 23 genes from the gene
entry list that were unmapped by DAVID (Table S9). These
include noncoding genes, lncRNA, ribosomal RNA (rRNA),
snoRNA, and miRNA.
Functional annotation clustering analysis was first per-
formed using DAVID’s default settings (Table S10) to iden-
tify overall gene sets that were highly enriched in MSC-
17 compared to UT-MSC. Annotation cluster 1 with the
highest enrichment score (3.58) had enriched terms for
genes residing in the extracellular region, roles in inflam-
matory response, response to wounding, defense responses,
signaling, and disulfide bonds (Table S10). Gene ontology
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Figure 3: Gene expression profile of MSC-17 (1), UT-MSC (2), and MSC-𝛾 (3) from 3 MSC donors determined with Affymetrix Human
Gene ST 2.0 microarrays. Supervised hierarchical clustering of genes differentially expressed between (a) MSC-𝛾 versus UT-MSC, (b) MSC-
17 versus UT-MSC, and (c) MSC-17 versus MSC-𝛾 determined by ANOVA 𝑝 value (condition pair) 𝑝 < 0.05 and fold change (linear) < −2
or >2. (a) 1278 and (b) 67 genes were differentially regulated between the treatment groups.The normalized expression value for each gene is
visualised by a colour gradient: blue represents low gene expression; red represents high gene expression.
analysis of biological processes also revealed that MSC-17
compared to MSC-𝛾 were upregulated and enriched for
genes involved in angiogenesis (e.g., angiogenin, CXCL12,
tissue plasminogen activator, and collagens), wound healing,
and chemotaxis responses (Table S14). Interestingly, some
gene sets were enriched for gene ontology terms such as
glycosylation and glycoproteins (Table S10), whichmay relate
to posttranslational modification processes [26, 27]. There
was also high enrichment of genes involved in chromatin
remodelling processes (enrichment score 7.35, Table S14),
suggesting the potential gene expression regulatory roles of
MSC-17.
Human MSC-17 were shown to be superior at regulating
T cell inflammatory responses by suppressing T cell prolifer-
ation, activation, and secretion of proinflammatory cytokines
[1]. In annotation cluster 3 (enrichment score 2.48, Table
S10), genes such as IL-6, C3, serum amyloid A1 (SAA1), and
lipopolysaccharide binding protein (LBP) were enriched for
regulation of immune responses. IL-6, SAA1, and LBP also
have roles in regulation of cytokine production.
Gene ontology analysis by DAVID functional annotation
clustering was also performed on the MSC-17 versus UT-
MSC and MSC-17 versus MSC-𝛾 gene lists to specifically
determine enriched gene sets for biological processes (Tables
S11, S14, and S15), molecular functions (Tables S12, S16),
and cellular components (Tables S13, S17, and S18) in MSC-
17. There was no significant enrichment of gene sets for
molecular functions in the downregulated gene list of MSC-
17 versus MSC-𝛾 comparison group.
MSC-17were previously shown tomediate Treg induction
via cell-cell contact dependent mechanisms [1]. To identify
potential cell surface candidate molecules that mediateMSC-
17 induction of Tregs, the cellular compartments of genes
enriched in the MSC-17 were also evaluated. Functional
enrichment for biological processes identified a set of upreg-
ulated genes (IL-6, CCL8, SLC22A3, STC1, and CXCL6) that
were enriched for the gene ontology term cell-cell signaling
(fold enrichment: 4.9; 𝑝 < 0.0148; annotation cluster 2,
Table S11). Chemokines CCL2, CCL8, and CXCL6 detected
by DAVID’s functional enrichment for molecular function
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(Table S12) showed evidence that these gene sets have a
different range of binding potential including chemokine
receptor, heparin, glycosaminoglycan, pattern, and polysac-
charide binding activities. These MSC-17 enriched genes,
mainly the chemokines and MMPs, were located in the
extracellular space (or) region (Table S13).
Biological processes (GOTERM BP FAT; Tables S11, S14)
and molecular functions (GOTERM MF FAT; Table S12) of
MSC-17 enriched genes were mainly associated with cell
migration and chemotaxis responses. MMPs were also highly
enriched in the MSC-17 groups. Specifically, MMP13 (FC
15.6) and MMP1 (FC 2.4) were induced in the MSC-17
groups as detected by microarray gene expression analysis
(Tables 2 and 3). DAVID’s bioinformatics analysis revealed
that these genes were enriched for gene ontology terms
such as secreted, extracellular space, signal, disulfide bond,
glycosylation, glycoproteins, and response to stimulus (Table
S10). The MSC-17 versus UT-MSC gene list when analysed
by DAVID functional annotation chart (default setting)
showed that these MMPs where highly enriched for metal
ion binding, peptidase, and collagen degradation functions
(Table S10).
3.4. MSC-17 Express Chemokines and Matrix Metallopro-
teinases. To validate the microarray data of MSC-17, upreg-
ulated genes were evaluated for their gene expression by RT-
PCR (Figure 4). IL-17A induced the expression of MMP1,
MMP13, CXCL6, C3, CH25H, and LBP in MSC as deter-
mined by microarray and validated by RT-PCR (𝑝 < 0.05).
CCL2 and CCL8 were highly expressed in both MSC-𝛾 and
MSC-17 compared to UT-MSC, consistent with the microar-
ray data. CCL2 gene expression increased by 8.2- and 5.9-
fold inMSC-𝛾 andMSC-17, respectively, relative to UT-MSC.
CCL8 expression on the other hand was comparable between
MSC-𝛾 andMSC-17. Although the gene expression levels var-
ied between the 3 MSC donors, these genes were consistently
upregulated relative to UT-MSC in all the MSC donors.
4. Discussion
IFN-𝛾 preactivation of human MSC induced the expres-
sion of various immunoregulatory molecules including IDO,
TLR3/4, IL-6, and PD-L1 that may enhance the inhibitory
activity ofMSC-𝛾 to mediate T cell suppression. IDO is a well
characterised immunosuppressive molecule expressed by
MSC upon induction with IFN-𝛾 [1, 28–30]. Administration
of IDO deficient MSC (IDO−/−MSC) or inhibition of IDO
activity resulted in accelerated kidney allograft rejection,
decreased intragraft, or circulating Tregs and showed absence
of donor-specific tolerance [29]. IDO−/−MSC were also inca-
pable of inhibiting donor DC maturation and function, thus
enabling DC to stimulate strong recipient T cell proliferative
responses [29]. Consistent with previous literature [28, 29,
31], gene expression analysis revealed that IDO was the
most highly induced gene in MSC-𝛾 and may be the key
candidatemolecule bywhichMSC-𝛾mediate enhancedT cell
immunosuppression [1].
MSC constitutively express a range of TLRs, including
TLR3 and TLR4 [32, 33]. Activation of TLR3 and (or)
TLR4 amplifies MSC trophic factors, antimicrobial activity,
and immunosuppressive potential, thereby enhancing MSC
therapeutic potency [33–36]. Both TLR3 and TLR4 were
upregulated in MSC-𝛾 compared to UT-MSC. Activation of
TLR3 and TLR4 signaling with poly I:C or LPS, respectively,
induced IDO expression in MSC [33]. TLR-driven induction
of IDO inMSC resulted in the degradation of tryptophan and
production of immunosuppressive kynurenines [33]. TLR3
activation has also been linked to expression of IL-6 in MSC
[34]. IL-6 mediates the inhibitory effects of MSC on DC
differentiation, maturation, and function [37, 38]. Consistent
with our previous report, the upregulation of IL-6 transcripts
inMSC-𝛾 and high protein concentrations of IL-6 inMSC-𝛾-
T cell coculture supernatants suggest thatMSC-𝛾 secreted IL-
6 may be involved in suppression of proinflammatory T cell
responses [1]. Nevertheless, TLR activation in MSC is known
to abrogate their immunosuppressive properties [39, 40].The
effects of TLR signaling in MSC are still not fully understood
and remain to be further investigated.
TLR3/4 preactivated MSC have enhanced leukocyte
binding activity mediated by the induction of the adhesion
molecule ICAM-1, consistent with upregulation of ICAM-1
in MSC-𝛾 [35]. ICAM-1 together with TLR3 and TLR4 were
among the genes enriched for the gene ontology termpositive
regulation of immune system process, suggesting a potential
biological role of TLR3/4 in MSC-𝛾 induction of ICAM-1
[35]. Additionally, the upregulation of chemokines such as
CXCL9, CXCL10, CXCL11, CXCL16, CCL2, CCL8, andCCL13
detected by microarray may facilitate T cell recruitment to
MSC-𝛾. Mouse MSC preactivated with IFN-𝛾 and TNF-
𝛼 induced CXCL9 and CXCL10 [41]. The production of
these chemokines was abrogated by IFN-𝛾 neutralization
[41]. Moreover, the blockade of CXCR3, a T cell receptor
for chemokines CXCL9 and CXCL10, eliminated T cell
chemotaxis towards MSC and subsequent MSC inhibition
of T cell proliferation [41]. These studies concluded that
cytokines induce MSC-expression of chemokines to drive
T cell recruitment into close proximity with MSC, enabling
MSC to suppress T cells through the secretion of immuno-
suppressive molecules [41, 42]. Chemokines also increased
the in vivo migratory properties of human MSC-𝛾 to sites of
inflammation in colitismousemodels [43]. Studies to validate
the functional role of human MSC-𝛾 derived chemokines
and ICAM-1 in the recruitment and subsequent modula-
tion of T cell responses as well as in MSC-𝛾 homing to
sites of inflammation in vivo are required. Hence, IFN-𝛾
directly induces an array of immunosuppressive molecules
in MSC and may further amplify the secretion of other
MSC-inhibitory molecules such as IDO, IL-6, and ICAM-
1 via TLR3/4 activation. MSC-𝛾 with higher proximity to
leukocytes may serve as an additional mechanism by which
MSC-𝛾 increase their modulatory activity on T cells.
Despite being highly immunosuppressive with enhanced
homing and reparative capacities, allogeneic MSC-𝛾 are
ineffective in vivo due to their increased immunogenicity
[44–46]. A large number of genes upregulated inMSC-𝛾were
involved in the antigen processing and presentation pathways
ofMHC classes I and II. Antigen processing and presentation
occurs via the cytosolic [47–51] or endocytic pathways
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Figure 4: Microarray gene expression validation by RT-PCR. Gene expression of MMP1, MMP13, CCL2, CCL8, CXCL6, C3, LBP, and CH25
in MSC detected by microarray was validated by RT-PCR following 5 days of IL-17A or IFN-𝛾 treatment of human MSC. ∗𝑝 < 0.05 versus
UT-MSC was determined by one-way ANOVA with post-Sidak multiple comparison test. Data are representative of 3 human MSC donors.
Error bars depict mean ± SD.
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[51, 52]. In the cytosolic pathway, degraded intracellular
proteins are transported to the rough endoplasmic reticulum
(RER) via TAP, a heterodimer consisting of TAP1 and TAP2.
These peptides are further trimmed by aminopeptidases
ERAP to enable optimal peptide loading onto MHC class
I molecules. MHC class I components comprise the class I
MHC 𝛼-chain and the B2M chain.ThisMHC class Imolecule
associates with the chaperonemolecules tapasin, calreticulin,
and ERp57. Tapasin (TAPBPL) recruits the MHC I molecules
into proximity to TAP, allowing efficient peptide loading onto
MHC class I molecules, subsequently stabilizing the peptide-
class I molecule complex. The class I MHC-peptide complex
is then transported to the plasma membrane for antigen-
peptide presentation to CD8+ T cells [47–51]. Induction of
ERAP, TAP2, TAPBPL, and B2M, genes involved in this
cytosolic pathway was evident in MSC-𝛾 and correlated with
the observed upregulation of MHC class I in these cells [1].
We have also shown that MHC class II is induced in MSC-
𝛾 [1]. In the endocytic pathway, assembly of MHC class
II occurs in RER where the 𝛼- and 𝛽-chain associate and
this newly synthesised class II MHC complex binds to the
invariant chain (Ii, CD74). As MHC class II-Ii complex is
translocated into the endosomal compartment, the Ii chain
is degraded, leaving the CLIP fragment (class II associated Ii
peptide) bound to the MHC II peptide binding cleft. HLA-
DM catalyses the exchange of CLIP with the antigenic pep-
tide. The MHC class II peptide complex is then transported
to the plasma membrane for antigen presentation to CD4+
T cells [51, 52]. We detected high expression of CD74 and
HLA-DM in MSC-𝛾, supporting the induction of MHC class
II on these cells. Alloimmune responses against UT-MSC are
mediated by the recognition of allogeneic MHC molecules
by recipient CD4+ and CD8+ memory T cells [53]. MHC
class II expression on allogeneicMSC is also known to induce
alloimmune responses in cocultures with MHC-mismatched
responder cells [54]. Therefore, the amplification of this
antigen processing and presentation machinery suggests that
MSC-𝛾 are highly immunogenic and can potently prime
proinflammatory T cell responses in allogeneic hosts.
Moreover, MSC-𝛾 were enriched for gene sets involved
in augmentation of the humoral immunity and comple-
ment pathways activation. Our data may explain previously
published data, where MSC-𝛾 infused mice had higher
levels of circulating anti-donor IgM and IgG alloantibodies,
which resulted in the rapid induction of antibody-mediated
rejection [44]. Although MSC-𝛾 lack the expression of
costimulatory signals (CD80, CD83, and CD86) to function
as APC tomediate direct T cell allorecognition and activation
[1, 55–58], we speculate that MSC-𝛾 induce allogeneic T cell
responses through the indirect or semidirect pathways of
allorecognition [21, 59]. Allogeneic MHC-peptide transfer
from MSC-𝛾 could be more rapid compared to UT-MSC
due to high expression of MHC molecules. This enables
allogeneicMHC-peptide to be recognised by recipient T cells
through the semidirect pathway. Understandingmechanisms
of MSC-𝛾 immunogenicity may enable the targeting of MSC
through different pathways of activation to increase their
immunomodulatory function whilst retaining MSC in a
nonimmunogenic and inert state.
Human MSC-17 showed superior suppression of T cell
responses and were able to induce Tregs with minimal
immunogenicity [1]. MSC constitutively express a range of
MMPs including MMP2, membrane type 1 MMP (MTI-
MMP), tissue inhibitor of MMP1 (TIMP1), and TIMP2
[60–62]. These MMPs are essential for MSC invasion and
migration across the extracellular matrix (ECM) as demon-
strated in in vitro transendothelial migration assays [62].
Absence of MMPs impairs MSC transmigration capacity
across Matrigels [60–62]. In response to IL-1𝛽 and TNF-
𝛼, MSC have also been shown to amplify the expression
of MMP2, MTI-MMP, and (or) MMP9 in MSC, thereby
promotingMSC invasiveness across the basementmembrane
[60]. Here, we demonstrated that IL-17A induced the gene
expression of MMP13 and MMP1 in MSC. These MMPs
were highly enriched for collagen degradation and metabolic
processes, suggesting that these factors may be essential for
MSC-17 to invade the ECM.
MSC-derived MMPs also have proteolytic activity on
chemokines [63, 64]. MMP processing of CC chemokines
convert the biochemical properties of the chemokine target
molecules from an agonist to an antagonist form with anti-
inflammatory properties in vivo [65]. MSC-derived MMP1
cleaves CCL2, leading to the generation of CCL2 with sup-
pressive properties on B cell production of immunoglobulins
and in CD4+ T cell activation [63, 64]. We showed that
MMP1, CCL2, and MMP13 were upregulated in human
MSC-17. Evaluating the functional role of MMP-processed
chemokine derivatives in MSC-17 immunomodulation on T
cells in this study remains to be elucidated.
MMP-2 andMMP-9 secreted byMSCare known to cleave
and reduce CD25 expression on T cells, thus impairing T cell
activation and proliferation [66]. Administration of MMP
inhibitors in an islet allotransplant model abrogated the
suppressive effect of MSC on alloreactive T cells, resulting in
allograft rejection. This study concluded that MMPs are cru-
cial for MSC immunosuppression [66]. We have previously
shown that MSC-17 further downregulated CD25 expression
on CD4+ effector T cells compared to UT-MSC, a process
partially mediated by cell contact dependent mechanisms
[1]. The involvement of MSC-17-derived MMP13 and MMP1
in downregulating CD25 on T cells has not been previ-
ously established. Blocking MMP13 activity using specific
inhibitors may provide insights on its role in inhibiting T cell
activation.
Apart from the upregulation of chemotactic transcripts,
MSC-17 were also enriched for genes involved inwound heal-
ing and angiogenesis. Tissue plasminogen activator (PLAT)
was upregulated in human bone marrow derived MSC-17
when compared toMSC-𝛾. PLAT was enriched for biological
processes involving cell motility, angiogenesis, and responses
to wounding. A previous study reported that IL-17A can
increase MSC migration in an in vitro wound healing assay
[7]. In a latter study, IL-17A was shown to enhance peripheral
blood-derived MSC migration in a wound healing assay by
inducing the expression of the urokinase type plasminogen
activator through the activation of ERK1,2-MAPK signaling
pathway [67]. Increased expression of the urokinase type
plasminogen activator has been reported to facilitate MSC
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transendothelial migration, potentially contributing to MSC
motility to sites of inflammation for tissue regeneration or
immunosuppression [67]. In other studies, tissue plasmino-
gen activators have also shown to support angiogenesis by
promoting vascular endothelial cell migration to ischemic
regions [68, 69]. These data suggest that MSC-17 in addition
to their potent immunosuppressive properties may benefit
disease conditions of ischemia injury that require tissue
repair and angiogenesis.
In this study, donor to donor variation may have limited
the robustness of ourmicroarray data to detect subtle changes
in MSC-17 gene expression profile. However, real-time PCR
data validated changes detected in the highly regulated genes
in MSC-17. More MSC-17 biological replicates may provide
further insights into other genes that are differently regulated.
5. Conclusions
Enhanced expression of MHC in allogeneic MSC-𝛾 increases
their immunogenicity and this may negatively impact MSC-
𝛾 potency in vivo. Nevertheless, we have highlighted novel
candidate immunosuppressive molecules and pathways in
whichMSC-𝛾 can be targeted in future studies to increase the
immunomodulatory capacity ofMSC.Wehave also identified
a few novel candidate molecules that may contribute to
the potent MSC-17 regulation of immune responses. These
candidate molecules can be explored for their regulatory
roles in MSC-17 suppression of T cell responses and in the
generation of Tregs in future studies.
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